BioSpaceOriginal article
Merck barred from making subcutaneous Keytruda in 8 European countries
RegulatoryrejectedKeytrudaNegative
AI Analysis
Summary
A patent court ruled in favor of Halozyme against Merck, barring Merck from manufacturing subcutaneous Keytruda in 8 European countries, despite the product's European approval last year.
Outcome Details
Patent court sided with Halozyme; Merck barred from making subcutaneous Keytruda in 8 European countries
Importance:7/10
Sentiment:
-0.85
patent disputeEuroperegulatory restrictionsubcutaneous formulation
Read the original article
Published by BioSpace on October 8, 2026 6:36 PM